Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 1;23(15):8538. doi: 10.3390/ijms23158538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of the CRH-R1 antagonist on Th2 cytokines and OVA-specific IgE in the ileum, and ileal permeability. Effects of the CRH-R1 antagonist on ileal mRNA expressions of IL-5 (A), IL-13 (B), and IL-4 (C) in WAS + OVA-treated mice. Effects of the CRH-R1 antagonist on ileal protein levels of IL-5 (D), IL-13 (E), and OVA-specific IgE (F) in WAS + OVA-treated mice. Effects of CRH-R1 antagonist on TEER (G), FITC-dextran flux (H), and mRNA expression of zonulin (I) in the ileum of WAS + OVA-treated mice. * p < 0.05, ** p < 0.01. CRH-R1, corticotropin-releasing hormone type 1 receptor; FITC, fluorescein isothiocyanate; IgE, immunoglobulin E; IL, interleukin; OVA, ovalbumin; TEER, transepithelial electrical resistance; Th2, type 2 helper T cell; WAS, water avoidance stress.